About Haley Chartres

This author has yet to write their bio.
Meanwhile lets just say that we are proud Haley Chartres contributed a whooping 172 entries.

Entries by Haley Chartres

Novartis’ Sandoz splurges on a trio of GSK antibiotics, doubling down with a $500M bet on a field struggling to combat resistant microbes

February 12, 2021 in , , /by

Article extract | “Novartis’ acquisition represents a double-down on an antibiotics field facing an existential crisis from resistant “super bugs” that have sent most major drugmakers running for the hills — including Novartis, which dumped its antibiotic R&D program in 2018. But adding ever-greater volume to their generic antibiotics portfolio could offer Novartis some bottom-line […]

ScoPo’s powerplays: Jazz Pharma’s $9.4b deal highlights pot plays

February 5, 2021 in , , /by

‘A huge acquisition in the international medical cannabis sector is set to give tailwinds to several ASX-listed marijuana companies, Scott Power says. Ireland-based Jazz Pharmaceuticals (NASDAQ:JAZZ) this week agreed to buy cannabinoid drugmaker GW Pharmaceuticals (NASDAQ:GWPH) for $US7.2 billion ($9.4 billion) – a 50 per cent premium to GW’s closing price on Tuesday.’ Click through to read the full article […]

Botanix soars after pot-up-nose study success

February 3, 2021 in , /by

‘Botanix Pharmaceuticals (ASX:BOT) shares have soared after a small clinical trial backed the feasibility of putting synthetic cannabis up the nose of surgical patients to prevent infections. While cannabis is of course mostly known for its psychoactive properties, a number of companies trying to unlock its therapeutic benefit and Botanix’s research has shown that cannabidiol (CBD) is […]

World first | Human clinical study shows synthetic CBD formula eradicates Staphylococcus Aureus

February 2, 2021 in , , , , /by

Philadelphia PA and Sydney Australia, 3 February 2021: Clinical stage synthetic cannabinoid company Botanix Pharmaceuticals Limited has today published positive data from a world first human clinical study, examining the safety, tolerability and efficacy of its BTX 1801 antimicrobial product for the eradication of Staphylococcus Aureus (Staph). Staph, also called golden staph, is a common […]

CBD oil kills gonorrhoea bacteria, potential for ‘much-needed new class of antibiotics’

January 20, 2021 in , , /by

Groundbreaking new research has found synthetic cannabidiol can kill bacteria associated with gonorrhoea, meningitis and legionnaires disease. The research, published in a peer-reviewed journal article in Communications Biology on Wednesday, explores antimicrobial activity of CBD and the potential to advance CBD analogs as a “much-needed new class of antibiotics”. It found the psychoactive component of […]

Qld researchers on how cannabis could be used to fight superbug

January 20, 2021 in , , /by

Queensland researchers are studying a component of medicinal cannabis for its potential as a new antibiotic, capable of killing superbugs. The big hope for scientists at the University of Queensland’s Institute for Molecular Bioscience is that synthetic cannabidiol, or CBD, the main non-psychoactive component of cannabis, could be developed into the first new class of […]

Journal article | “The antimicrobial potential of cannabidiol”

January 20, 2021 in , , , /by

An important research project testing the targeted capabilities of our antimicrobial platform, conducted in collaboration with The University of Queensland, has been published in Communications Biology ­– a leading peer-reviewed journal by Nature Research. The research article titled “The antimicrobial potential of cannabidiol” reveals the unique mechanism through which synthetic cannabidiol can kill the bacteria […]